Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.33 |
| ▸ | CPB1 | P15086 | 4/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | TRHR | P34981 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293206 | 0.88 | CYP2C9 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL1133628 | 0.88 | CYP2C9 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13187468 | 0.85 | CYP2C9 (0.37) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Sulfurous Acid SCHEMBL28479956 | 0.82 | CYP2C9 (0.37) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL15132911 | 0.78 | CYP2C9 (0.47) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Aspartic Acid SCHEMBL22061784 | 0.77 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| Glycinebetaine SCHEMBL16755435 | 0.76 | CYP2C9 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL17641843 | 0.75 | CYP2C9 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13933558 | 0.75 | CYP2C9 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL13612080 | 0.75 | CYP2C9 (0.47) | CYP2C9TSHRCYP2C19MTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-8790691-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-29 | — | — | US | disclosed |
| US-8568772-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8545876-B1 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-8545877-B2 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | CYP2C9 1602/4885TSHR 3093/4885CYP2C19 2058/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | CYP2C9 3533/4885TSHR 2672/4885CYP2C19 4132/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | CYP2C9 1602/4885TSHR 3093/4885CYP2C19 2058/4885 |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | CYP2C9 1602/4885TSHR 3093/4885CYP2C19 2058/4885 |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | CYP2C9 1602/4885TSHR 3093/4885CYP2C19 2058/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | CYP2C9 3533/4885TSHR 2672/4885CYP2C19 4132/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | CYP2C9 3533/4885TSHR 2672/4885CYP2C19 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.